General characteristics and clinical data of the subjects included in the study. by Spela Kokelj (8356644)

Subjects:

Distribution of continuous variables of all 3 visits of group 1 (placebo) and group 2 (placebo) that have no significant difference among the groups. by Nattapon Riengvirodkij (11268720)

Subjects:

Decreasing oxygen saturation with corresponding levels of NLR and D-dimer for understanding the interplay of inflammation. by Narendran Gopalan (110148)

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Clinical data of the control and CoA cases in our cohort. by Inmaculada Villanueva-Baxarias (21454246)

Subjects:

Centrifuged FMT products consistently exhibit the lowest median log₁₀ drop of CFU/g following freezing and lyophilization. In contrast, unprocessed feces exhibited the g... by Nina K. Randolph (21030732)

The table shows the significant and non-significant altered group with different parameters. by Ashraf Attia Mahmoud (21262201)

Presentation 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.pptx by Juan Chen (61123)

“…However, the evidence and regulatory mechanisms underlying decreased BDNF levels in CKD remain inconclusive.</p>Methods<p>This study systematically evaluated circulating BDNF alterations in CKD patients through a meta-analysis of clinical studies involving 1,549 participants, complemented by experimental validation in unilateral ureteral obstruction (UUO) mice and single-cell transcriptomic database analysis to investigate tissue-specific BDNF protein expression and regulatory patterns.…”

HFD decreases ITM and alters metabolic homeostasis. by Tong Yue (6033305)

Clinical characteristics of patients and controls. by Duangnapa Roongpiboonsopit (12829198)

Subjects:

Data Sheet 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.docx by Juan Chen (61123)

“…However, the evidence and regulatory mechanisms underlying decreased BDNF levels in CKD remain inconclusive.</p>Methods<p>This study systematically evaluated circulating BDNF alterations in CKD patients through a meta-analysis of clinical studies involving 1,549 participants, complemented by experimental validation in unilateral ureteral obstruction (UUO) mice and single-cell transcriptomic database analysis to investigate tissue-specific BDNF protein expression and regulatory patterns.…”

TBSS results showing significant AxD and RD changes at baseline and the follow-up. by Sewon Lim (21989785)

S9 Data - Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases by Feng Gao (3548)

Subjects:

S3 Data - Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases by Feng Gao (3548)

Subjects:

S7 Data - Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases by Feng Gao (3548)

Subjects:

S2 Data - Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases by Feng Gao (3548)

Subjects:

S4 Data - Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases by Feng Gao (3548)

Subjects:

S6 Data - Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases by Feng Gao (3548)

Subjects:

S5 Data - Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases by Feng Gao (3548)

Subjects:

S8 Data - Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases by Feng Gao (3548)

Subjects: